Prenetics
Script error: No such module "Draft topics".
Script error: No such module "AfC topic".
Prenetics is a health sciences company with a focus on genomics, headquartered in Hong Kong. It is publicly traded on the NASDAQ under the ticker symbol "PRE."[1] The company operates through three main business divisions: CircleDNA for prevention, Insighta for early detection, and ACT Genomics for treatment.
Circle DNA[edit]
CircleDNA, the prevention division of Prenetics, employs whole exome sequencing to offer direct-to-consumer, non-invasive DNA tests for home use.[2]
Insighta[edit]
Insighta is a joint venture between Prenetics and scientist Professor Dennis Lo, with a focus on developing technologies aimed at the early detection of multiple types of cancer.[3]
ACT Genomics[edit]
ACT Genomics specializes in precision medicine, particularly in the field of cancer treatment.[4]
History[edit]
Prenetics was co-founded in 2014 by Danny Yeung and Dr. Lawrence Tzang in Hong Kong. Subsequently, it launched iGenes, a pharmacogenetics test designed to assist physicians and patients in medication selection.[5]
In 2016, Prenetics raised US$10 million in a Series A venture round. In 2017, Prenetics raised US$40 million in a Series B offering. [1]
In 2018, Prenetics acquired DNAfit, a UK-based company, and later that year launched its CircleDNA product. [6] The company added whole exome sequencing technology to its offerings in 2019 [2]
In 2020, Prenetics initiated Project Screen and acquired Oxsed, extending their capabilities in COVID-19 testing. [7] [8]
In 2021, the company announced a merger with Artisan Acquisition. Prenetics also launched Circle Healthpod within the same year. [9]
It also formed a partnership to develop health passports, providing COVID-19 health screenings to over 100 companies.[10]
[10] On May 18, 2022, Prenetics became the first Hong Kong-based company to be publicly listed on NASDAQ.
References[edit]
- ↑ 1.0 1.1 Tan, Emily (September 15, 2021). "Hong Kong start-up Prenetics to list in the U.S. through $1.7 billion SPAC deal". CNBC.
- ↑ 2.0 2.1 "Gene genie: how DNA tests may help you beat disease and lose weight". South China Morning Post. February 2, 2021.
- ↑ "Exclusive: Hong Kong's DNA pioneers launch blood tests to find cancer". South China Morning Post. June 26, 2023.
- ↑ "Hong Kong-based cancer diagnostics providers ACT Genomics, Sanomics merge". South China Morning Post. November 22, 2021.
- ↑ Chan, Wing; Li, Man S.; Sundaram, Senthil K.; Tomlinson, Brian; Cheung, Pik Y.; Tzang, Chi H. (January 6, 2019). "CYP2D6 allele frequencies, copy number variants, and tandems in the population of Hong Kong". Journal of Clinical Laboratory Analysis. 33 (1): e22634. doi:10.1002/jcla.22634. PMC 6430334. PMID 30069923.
- ↑ "Prenetics Launches Circle, a Consumer DNA Testing Platform". www.biospectrumasia.com.
- ↑ "Exclusive: Hong Kong start-up Prenetics acquires rapid Covid-19 test technology". South China Morning Post. October 30, 2020.
- ↑ Partridge, Joanna (March 21, 2021). "Is this the future of office work – the pop-up car park Covid test pod?". The Guardian.
- ↑ Yang, Jing (September 15, 2021). "Prenetics, a Covid-19 Testing Startup, to Go Public in SPAC Merger". WSJ – via www.wsj.com.
- ↑ 10.0 10.1 "Covid-Testing Unicorn Is Plotting Bets for Post-Virus World". Bloomberg. May 18, 2022 – via www.bloomberg.com.
This article "Prenetics" is from Wikipedia. The list of its authors can be seen in its historical and/or the page Edithistory:Prenetics. Articles copied from Draft Namespace on Wikipedia could be seen on the Draft Namespace of Wikipedia and not main one.
